South Korea's biopharmaceutical company Celltrion said Friday that it has begun primate toxicology studies for CT-G32, its next-generation obesity drug candidate, as the final preclinical stage before human trials. Celltrion develops quadruple-action obesity drug
5 months ago
63
South Korea's biopharmaceutical company Celltrion said Friday that it has begun primate toxicology studies for CT-G32, its next-generation obesity drug candidate, as the final preclinical stage before human trials. 
English (US) ·